You are here

Article Text

Article menu
Download PDFPDF
Letters
Campylobacter fetus infection in three rheumatoid arthritis patients treated with rituximab
  1. Alain Meyer1,
  2. Arnaud Theulin1,
  3. Emmanuel Chatelus1,
  4. Xavier Argemi2,
  5. Christelle Sordet1,
  6. Rose Marie Javier1,
  7. Yves Hansmann2,
  8. Jean Sibilia1,
  9. Jacques-Eric Gottenberg1
  1. 1Hôpitaux Universitaires de Strasbourg-Hautepierre, Service de Rhumatologie, Strasbourg, France
  2. 2Hôpitaux Universitaires de Strasbourg-Nouvel Hôpital Civil, Service des Maladies Infectieuses, Strasbourg, France
  1. Correspondence to Dr Alain Meyer and Dr Jacques-Eric Gottenberg, Service de Rhumatologie, Hôpital de Hautepierre, 1, avenue Molière, 67098 Strasbourg, Cedex, France; alain.meyer1{at}chru-strasbourg.fr; jacques-eric.gottenberg{at}chru-strasbourg.fr

https://doi.org/10.1136/annrheumdis-2011-200719

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Campylobacter fetus osteoarticular or prosthetic material infection or cellulitis has been rarely described, mainly in immunocompromised patients. Among these cases, only two patients had inflammatory systemic diseases treated with rituximab (RTX).1 We report three patients with rheumatoid arthritis (RA) treated with RTX who developed osteoarticular or cutaneous infection due to C fetus.

    The patients were aged 71, 53 and 80 years with disease durations of 24, 13 and 19 years, respectively. All patients had a history of diabetes. Patients 1 and 3 had hypertensive cardiomyopathy, while patient 2 suffered from chronic obstructive pulmonary disease (COPD) and patient 3 from bronchiolitis obliterans organising pneumonia. All patients were co-treated with corticosteroids (10 mg/day) and disease-modifying antirheumatic …

    View Full Text

    Footnotes

    • AM and AT are joint first author.

    • Competing interests CS, JS and J-EG have received honoraria (<$10,000) from Roche, Abbott, MSD, Pfizer, UCB Pharma, Bristol-Myers or Squibb and have served as clinical trial investigators for these companies.

    • Patient consent Oral consent was obtained from all patients.

    • Ethics approval For each patient, ethics approval was obtained from the ethics committee of Strasbourg University Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.